1. Home
  2. IDT vs URGN Comparison

IDT vs URGN Comparison

Compare IDT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDT Corporation Class B

IDT

IDT Corporation Class B

HOLD

Current Price

$52.73

Market Cap

1.2B

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$29.33

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDT
URGN
Founded
1990
2004
Country
United States
United States
Employees
1925
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
IDT
URGN
Price
$52.73
$29.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$80.00
$29.29
AVG Volume (30 Days)
93.8K
829.4K
Earning Date
06-04-2026
05-06-2026
Dividend Yield
0.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$4.34
$129.09
Revenue Next Year
N/A
$70.96
P/E Ratio
$15.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.72
$3.61
52 Week High
$71.12
$32.37

Technical Indicators

Market Signals
Indicator
IDT
URGN
Relative Strength Index (RSI) 53.97 60.56
Support Level $46.85 $17.86
Resistance Level $53.32 $30.00
Average True Range (ATR) 1.44 2.03
MACD -0.08 -0.07
Stochastic Oscillator 38.74 65.51

Price Performance

Historical Comparison
IDT
URGN

About IDT IDT Corporation Class B

IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: